Market Access News | pharmaphorum

News

uniQure set for May FDA verdict on Huntington's gene therapy

The FDA has started its review of uniQure's gene therapy for neurodegenerative disorder Huntington's, but will require an advisory committee meeting.

News

Ultragenyx gets first Euro nod for rare disease drug Dojolvi

Several years after its US approval, Ultragenyx's therapy for long-chain fatty acid oxidation disorders, Dojolvi, has been greenlit in the UK.

News

Hutchmed, AZ file Orpathys for lung cancer on ESMO data

Hutchmed/AstraZeneca's Orpathys is now under review in Europe and Japan for MET-driven/EGFR-mutated lung cancer, shortly after it was filed in the US.

News

Inovio stock rises 2.5-fold on plasmid DNA drug approval

Inovio Pharma's plasmid DNA-based Voceryq has become the second drug approved in the US for adults with recurrent respiratory papillomatosis.

News

HHS doubles down on controversial peptides plan

HHS unveils an enforcement holiday to manufacture of unapproved peptides - before the FDA decides if they should be allowed in compounded medicines.

News

UK budget includes £1bn biopharma investment package

UK Chancellor John Healey's first Budget speech included a £1bn-plus industry investment package at sites in Manchester, Oxford, and Loughborough.

uniQure set for May FDA verdict on Huntington's gene therapy

Ultragenyx gets first Euro nod for rare disease drug Dojolvi

Hutchmed, AZ file Orpathys for lung cancer on ESMO data

Inovio stock rises 2.5-fold on plasmid DNA drug approval

HHS doubles down on controversial peptides plan

UK budget includes £1bn biopharma investment package

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks